Is Buprenorphine legal in Guyana?

Legal status

Controlled, and the applied cell reaches the right answer by a route it never states. The string buprenorphine does not appear anywhere in the consolidation [Certain]. What the Act does print, in the First Schedule, is a list closing «(4) Narcotine (5) Papaverine (6) Thebaine, and their preparations, derivatives and salts». Buprenorphine is a semi-synthetic derivative of thebaine, so the derivatives limb of that entry is the route, and the entry the cell should cite is «Thebaine» and not a Spanish search term. Oripavine also appears, inside the chemical name printed against «Etorphine». This is a reading of the derivatives limb and not a printed entry for buprenorphine, and the cell says so rather than passing it off as one. Whether a court would read derivatives that widely is not settled here. The version horizon, stated outright because an absence without one expires silently and says nothing about having expired: the list read is the First and Second Schedules to the Narcotic Drugs and Psychotropic Substances (Control) Act, Cap. 10:10 as it stands at L.R.O. 1/2012, and the Minister may amend the Schedules by order, so this does not rule out a later addition.

Consequences if caught

Capital exposure: none. Guyana's Cap. 10:10 carries no death penalty at any tier; section 5(1) sets the indictable trafficking ceiling at life imprisonment, so the worst outcome this Act reaches is a life sentence. No per-substance number is printed for this row, so the schedule supplies the placement and section 5(1) supplies the ceiling: there is no weight band, no tariff and no quantity threshold attached to «buprenorfina» itself. Opioid substitution material is identified by its active ingredient, so a film or a tablet has to be shown to contain buprenorphine rather than another maintenance drug. What the ceiling does not do is say where inside it a case lands, and the dossier records no sentencing range, no minimum and no fine figure for this row.

If prescribed or medical

Deferred, and the deferral is the honest answer. The dossier carries no Guyanese prescription rule, no import permit route, no personal medicine allowance and no Ministry authorisation procedure at all, so there is no traveller rule here to state and none is invented. What is established is the placement: «buprenorfina» sits in the First and Second Schedules to Cap. 10:10, which is what any authorisation would have to be granted against. Buprenorphine is most often carried as opioid substitution treatment, which is precisely the case where an import permit route would matter, and the dossier records no such route for Guyana. Settle the medical route with the Guyanese authorities before travelling rather than from this cell.

Documentation

A treatment programme letter is worth carrying alongside the prescription, although nothing in the dossier says Guyana accepts one. Carry any controlled medicine in its original dispensing packaging with the prescription and a prescriber's letter naming the patient, the active ingredient, the dose and the treatment period, because the schedule is read against the active ingredient and not against the product name. Nothing in the dossier confirms that Guyana accepts any of that, so treat it as the minimum a traveller can show and not as a permission. The First and Second Schedules were read for this row on 20 September 2026 and the entry the dossier recorded was «buprenorfina».

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Guyana’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.